CryoPort, Inc. (NASDAQ:CYRX) Director Ramkumar Mandalam Sells 40,728 Shares

CryoPort, Inc. (NASDAQ:CYRX - Get Free Report) Director Ramkumar Mandalam sold 40,728 shares of the firm's stock in a transaction that occurred on Tuesday, July 22nd. The shares were sold at an average price of $7.24, for a total value of $294,870.72. Following the completion of the transaction, the director directly owned 92,328 shares in the company, valued at $668,454.72. The trade was a 30.61% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Ramkumar Mandalam also recently made the following trade(s):

• On Tuesday, June 24th, Ramkumar Mandalam sold 13,321 shares of CryoPort stock. The stock was sold at an average price of $7.01, for a total transaction of $93,380.21.
• On Friday, June 13th, Ramkumar Mandalam sold 624 shares of CryoPort stock. The shares were sold at an average price of $6.80, for a total value of $4,243.20.
• On Thursday, June 12th, Ramkumar Mandalam sold 1,895 shares of CryoPort stock. The stock was sold at an average price of $7.01, for a total value of $13,283.95.
• On Wednesday, June 11th, Ramkumar Mandalam sold 8,193 shares of CryoPort stock. The shares were sold at an average price of $7.06, for a total value of $57,842.58.
• On Monday, June 9th, Ramkumar Mandalam sold 5,622 shares of CryoPort stock. The stock was sold at an average price of $7.06, for a total value of $39,691.32.

CryoPort Price Performance

NASDAQ CYRX traded down $0.20 during trading on Monday, reaching $7.65. 434,841 shares of the company traded hands, compared to its average volume of 394,242. CryoPort, Inc. has a 1-year low of $4.58 and a 1-year high of $9.66. The company has a market cap of $383.57 million, a price-to-earnings ratio of -3.27 and a beta of 1.89. The stock's 50 day moving average price is $6.94 and its two-hundred day moving average price is $6.58. The company has a debt-to-equity ratio of 0.51, a quick ratio of 5.24 and a current ratio of 5.56.

CryoPort (NASDAQ:CYRX - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.01. CryoPort had a negative net margin of 50.15% and a negative return on equity of 11.03%. The firm had revenue of $41.04 million for the quarter, compared to analysts' expectations of $56.19 million. As a group, analysts anticipate that CryoPort, Inc. will post -0.99 EPS for the current year.

Institutional Investors Weigh In On CryoPort

A number of hedge funds have recently added to or reduced their stakes in the stock. Rhumbline Advisers boosted its holdings in CryoPort by 23.8% in the first quarter. Rhumbline Advisers now owns 78,320 shares of the company's stock valued at $476,000 after acquiring an additional 15,036 shares during the last quarter. Graham Capital Management L.P. lifted its holdings in CryoPort by 24.9% in the fourth quarter. Graham Capital Management L.P. now owns 28,460 shares of the company's stock valued at $221,000 after buying an additional 5,667 shares during the period. Lazard Asset Management LLC acquired a new stake in CryoPort during the 4th quarter worth $51,000. ProShare Advisors LLC bought a new stake in shares of CryoPort during the 4th quarter valued at $95,000. Finally, Readystate Asset Management LP lifted its stake in shares of CryoPort by 91.6% in the 1st quarter. Readystate Asset Management LP now owns 500,344 shares of the company's stock valued at $3,042,000 after purchasing an additional 239,153 shares during the period. Institutional investors own 92.90% of the company's stock.

Analyst Ratings Changes

CYRX has been the topic of several research analyst reports. BTIG Research lowered their price objective on shares of CryoPort from $13.00 to $10.00 and set a "buy" rating on the stock in a research note on Monday, July 7th. Roth Mkm reaffirmed a "buy" rating and set a $15.00 price objective on shares of CryoPort in a research report on Tuesday, April 1st. Needham & Company LLC reiterated a "buy" rating and issued a $11.00 target price on shares of CryoPort in a research note on Thursday, May 8th. Morgan Stanley lowered their price target on CryoPort from $8.00 to $7.00 and set an "equal weight" rating on the stock in a research note on Monday, May 5th. Finally, Guggenheim reiterated a "buy" rating and issued a $10.00 price objective on shares of CryoPort in a research report on Wednesday, April 16th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $11.11.

About CryoPort

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.